Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Rush University Medical Center
Conditions and Treatments
Search by Topic or Doctor's Name
At the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.
— Octavio Vega, MD, internist
I enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.
— Patricia Graham, MD, internist
Hear more from doctors at Rush.
Directions and Parking
Health and Wellness
Health News and Advice to Fit Your Life
The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.
5 Things You Can Do to Prevent CancerHow you can devise a cancer prevention action plan.
Combating Social Media DysmorphiaHow to love yourself — and your selfies — without filters or fillers.
About RushThe Rush SystemPatient StoriesNational Recognition and AccreditationsRush News
Quality and Safety at RushPatient Satisfaction and FeedbackRush in the CommunityDiversity and Inclusion
Disability Rights and AccommodationsCommitment to LGBTQ Health CareVolunteeringBondholder Information
R01 colonoscopy research study.
A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.
Safety and efficacy of permanently implantable LDR CivaSheet® in combination with external beam radiation in the treatment of pancreatic cancer.
Food timing and alcohol study for patients who had advanced tubular adenoma.
Study to determine if subjects with colorectal cancers will benefit from eflornithine and sulindac.
Phase I trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.
A randomized phase II study of nivolumab after combined modality therapy (CMT) in high risk anal cancer.
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair.